In response to the rise in opioid overdose deaths nationwide, pharmaceutical companies have developed formulations of prescription opioids designed to prevent tampering or abuse. These “abuse-deterrent” forms, however, are expensive and may not actually have the intended effect, say experts from Yale School of Medicine.
In a Perspective piece published in the New England Journal of Medicine (NEJM), Drs. William Becker and David Fiellin explore the potential pitfalls and benefits of moving toward greater prescribing of abuse-deterrent opioids.
Published: Friday, June 2, 2017
